Candesartan for High Blood Pressure in Obesity

(END-RF Trial)

Recruiting in Palo Alto (17 mi)

Overseen by Ryan Harris, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Augusta University

Trial Summary

What is the purpose of this trial?

This trial will use chemicals and a drug called Candesartan to study how they affect certain receptors related to blood pressure. It focuses on obese individuals who often have high levels of a substance called ET-1, which is linked to high blood pressure. By blocking these receptors, the study aims to see if it can improve their function and help lower blood pressure in obese people. Candesartan has been studied extensively for its effects on blood pressure, particularly in hypertensive and obese patients.

Research Team

Ryan Harris, PhD

Principal Investigator

Augusta University

Eligibility Criteria

This trial is for adults aged 18-40 who are dealing with high blood pressure and obesity. It's not open to those with cardiovascular, lung, kidney, liver, brain diseases or metabolic disorders; pregnant individuals; people on meds that affect blood vessels or anticoagulants like aspirin; those with anemia, postmenopausal women, or uncontrolled hypertension.

Inclusion Criteria

I am between 18 and 40 years old.

Exclusion Criteria

You are pregnant.

My blood pressure is not controlled, even with treatment.

I have a heart, lung, kidney, liver, brain, or metabolic condition.

Treatment Details

Interventions

• Candesartan (Angiotensin II Receptor Blocker)
• Placebo (Drug)

Trial Overview The study is testing the effects of Candesartan (a drug) against a placebo to see if it can improve how well ETB receptors work in obese individuals. This could help understand if these receptors play a role in developing high blood pressure due to obesity.

Participant Groups

Group I: Candesartan Experimental Treatment 1 Intervention

Sub chronic (7 days) Candesartan (16 mg/day)

Group II: Placebo Placebo Group 1 Intervention

Endothelial function will be determined following a seven day treatment of placebo

Who Is Running the Clinical Trial?

Augusta University

Lead Sponsor

Trials

219

Recruited

85,900+

Dr. David C. Hess

Augusta University

Chief Executive Officer since 2017

MD from Johns Hopkins University, Neurology residency and Vascular Neurology fellowship at Augusta University

Dr. David C. Hess

Augusta University

Chief Medical Officer since 2017

MD from University of Maryland School of Medicine

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials

3,987

Recruited

47,860,000+

Dr. Gary H. Gibbons

National Heart, Lung, and Blood Institute (NHLBI)

Chief Executive Officer since 2012

MD from Harvard Medical School

Dr. James P. Kiley

National Heart, Lung, and Blood Institute (NHLBI)

Chief Medical Officer since 2011

MD from University of California, San Francisco